(297 days)
No
The device description and performance studies focus on laser technology and its physical effects, with no mention of AI or ML algorithms for analysis, control, or interpretation.
No
The device is indicated for non-invasive aesthetic treatment, not for treating or diagnosing a disease or condition.
No
The device is indicated for non-invasive aesthetic treatment for temporary circumference reduction, which is a treatment function, not a diagnostic one.
No
The device description explicitly details hardware components such as a main unit, laser diode cluster probes and pads, power supply, control circuits, LCD display, buttons, and a key switch. This indicates it is a physical medical device with integrated software, not a software-only device.
Based on the provided information, the i-lipo™ Low Level Laser System is not an In Vitro Diagnostic (IVD) device.
Here's why:
- IVD Definition: In Vitro Diagnostics are devices intended for use in the collection, preparation, and examination of specimens taken from the human body (such as blood, urine, or tissue) to provide information for the diagnosis, monitoring, or treatment of disease or conditions.
- i-lipo™ Function: The i-lipo™ system uses laser energy applied externally to the patient's skin to promote the disruption of fat cells for temporary circumference reduction. It does not involve the analysis of any biological specimens taken from the body.
- Intended Use: The intended use is for "Non-invasive aesthetic treatment for the temporary reduction in circumference of the waist." This is a cosmetic/aesthetic application, not a diagnostic one.
Therefore, the i-lipo™ Low Level Laser System falls under the category of a therapeutic or aesthetic device, not an IVD.
N/A
Intended Use / Indications for Use
The Chromogenex Technologies Limited i-lipo™ Low Level Laser System is indicated for Non-invasive aesthetic treatment for the temporary reduction in circumference of the waist.
Product codes
OLI
Device Description
The i-lipo™ System consists of a main unit, and applied parts consisting of various laser diode cluster probes and pads. The Main Unit contains the mains input, fuses, power supply, relay, control circuits, LCD display, membrane function buttons, emergency stop, and key switch. The cluster probes and pads, which are placed against the patients skin, contain the Laser diodes. Laser energy promotes disruption of adipocyte cells within the fat layer for release of fat and lipids from these cells for non-invasive aesthetic use.
Mentions image processing
Not Found
Mentions AI, DNN, or ML
Not Found
Input Imaging Modality
Not Found
Anatomical Site
waist
Indicated Patient Age Range
Not Found
Intended User / Care Setting
Not Found
Description of the training set, sample size, data source, and annotation protocol
Not Found
Description of the test set, sample size, data source, and annotation protocol
Not Found
Summary of Performance Studies (study type, sample size, AUC, MRMC, standalone performance, key results)
Randomised, blinded, placebo controlled circumferential reduction studies of the selected treatment area have been performed, which demonstrates the efficacy of the device, following 8 sessions of treatment each of 20 minutes duration, delivered 2 to 3 times per week over a 3 week period. After each treatment session, a 30-40 minute cardiovascular exercise was completed, based upon the participants existing exercise regimen. Exercise sessions ensure that released fatty acids and glycerol are utilised rather than restored back in the body.
Key Metrics (Sensitivity, Specificity, PPV, NPV, etc.)
Not Found
Predicate Device(s)
Reference Device(s)
Not Found
Predetermined Change Control Plan (PCCP) - All Relevant Information
Not Found
§ 878.5400 Low level laser system for aesthetic use
(a)
Identification. A Low Level Laser System for Aesthetic Use is a device using low level laser energy for the disruption of adipocyte cells within the fat layer for the release of fat and lipids from these cells for noninvasive aesthetic use.(b)
Classification. Class II (special controls). The special control for this device is the FDA guidance document entitled “Guidance for Industry and Food and Drug Administration Staff; Class II Special Controls Guidance Document: Low Level Laser System for Aesthetic Use.” See § 878.1(e) for the availability of this guidance document.
0
Chromogenex Technologies Limited - i-lipo™ -Traditional 510(k) Application May 2011
510(k) Summary
MAR 2 3 2012
This summary of 510(k) safety and effectiveness information is being submitted in accordance with the requirements of SMDA 1990 and 21 CFR 807.92.
Submitter: A. Chromogenex Technologies Limited Units 1-2 Heol Rhosyn Parc Dafen Llanelli Carmarthenshire SA14 8QG UK
Phone: +44 (0) 1554 755444 +44 (0) 1554 755333 Fax:
Contact: Mr Peter R Bevan (Quality Manager)
Date Prepared: May 2011
B. Device Names:
Classification name Low Level Laser System for Aesthetic Use Common/usual name Low Level Laser System i-lipo™ System Proprietary name
C. Predicate Devices:
Chromogenex Technologies Limited - ilipo Ultra System - K101366 Erchonia Medical Inc - Erchonia ML Scanner - K082609
D. Device Description:
The i-lipo™ System consists of a main unit, and applied parts consisting of various laser diode cluster probes and pads. The Main Unit contains the mains input, fuses, power supply, relay, control circuits, LCD display, membrane function buttons, emergency stop, and key switch. The cluster probes and pads, which are placed against the patients skin, contain the Laser diodes. Laser energy promotes disruption of adipocyte cells within the fat layer for release of fat and lipids from these cells for non-invasive aesthetic use.
ய் Intended Use:
The Chromogenex Technologies Limited i-lipo™ Low Level Laser System is indicated for Non-invasive aesthetic treatment for the temporary reduction in circumference of the waist.
1
F. Comparison with the Predicate Devices:
The i-lipo is substantially equivalent to the predicates with respect to intended use and technological characteristics.
G. Clinical Testing
Randomised, blinded, placebo controlled circumferential reduction studies of the selected treatment area have been performed, which demonstrates the efficacy of the device, following 8 sessions of treatment each of 20 minutes duration, delivered 2 to 3 times per week over a 3 week period. After each treatment session, a 30-40 minute cardiovascular exercise was completed, based upon the participants existing exercise regimen. Exercise sessions ensure that released fatty acids and glycerol are utilised rather than restored back in the body.
H. Non Clinical Testing
Safety testing has been performed to EN 60950 for General Safety and, EN60601-2-22 and EN60825 standards for Medical Electrical Equipment - Particular requirements for safety - Specification for diagnostic and therapeutic laser equipment. Electromagnetic compatibility has been tested to EN60601-2 - Medical Electrical Equipment - Part 1: General Requirements for Safety 2.
I. Conclusion
Based on the technological characteristics and clinical testing, the i-lipo™ is substantially equivalent to the above named predicate devices, for the intended use.
2
DEPARTMENT OF HEALTH & HUMAN SERVICES
Image /page/2/Picture/1 description: The image shows the logo for the Department of Health & Human Services - USA. The logo consists of a circular seal with the text "DEPARTMENT OF HEALTH & HUMAN SERVICES - USA" arranged around the perimeter. Inside the circle is a stylized design of three wavy lines, resembling an abstract representation of a human form or a symbol of health and well-being.
Public Health Service
Food and Drug Administration 10903 New Hampshire Avenue Document Control Room -WO66-G609 Silver Spring, MD 20993-0002
Chromogenex Technologies Limited % Mr. Peter R. Bevan Quality and Regulatory Manager Units1 and 2 Heol Rhosyn Parc Dafen Llanelli Carmarthenshire SA14 8QG
Re: K111501
Trade/Device Name: i-lipo™ System Regulation Number: 21 CFR 878.5400 Regulation Name: Low level laser system for aesthetic use Regulatory Class: II Product Code: OLI Dated: March 5, 2012 Received: March 7, 2012
Dear Mr. Bevan:
We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration. Please note: CDRH does not evaluate information related to contract liability warranties. We remind you, however, that device labeling must be truthful and not misleading.
If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 898. In addition, FDA may publish further announcements concerning your device in the Federal Register.
Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act
MAR 2 3 2012
3
Page 2 - Mr. Peter R. Bevan
or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Part 801); medical device reporting (reporting of medical device-related adverse events) (21 CFR 803); good manufacturing practice requirements as set forth in the quality systems (QS) regulation (21 CFR Part 820); and if applicable, the electronic product radiation control provisions (Sections 531-542 of the Act); 21 CFR 1000-1050.
If you desire specific advice for your device on our labeling regulation (21 CFR Part 801), please go to http://www.fda.gov/AboutFDA/CentersOffices/CDRH/CDRHOffices/ucm115809.htm for the Center for Devices and Radiological Health's (CDRH's) Office of Compliance. Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21CFR Part 807.97). For questions regarding the reporting of adverse events under the MDR regulation (21 CFR Part 803), please go to
http://www.fda.gov/MedicalDevices/Safety/ReportaProblem/default.htm for the CDRH's Office of Surveillance and Biometrics/Division of Postmarket Surveillance.
You may obtain other general information on your responsibilities under the Act from the Division of Small Manufacturers, International and Consumer Assistance at its toll-free number (800) 638-2041 or (301) 796-7100 or at its Internet address
http://www.fda.gov/MedicalDevices/Resourcesfor You/Industry/default.htm.
Sincerely yours,
Ton Duta
Mark N. Melkerson Director Division of Surgical, Orthopedic and Restorative Devices Office of Device Evaluation Center for Devices and Radiological Health
Enclosure
4
Chromogenex Technologies Limited - i-lipo™ -Traditional 510(k) Application May 2011
Indications for Use
510(k) Number (if known): 11.150 1
Device Name: _ i-lipo™ System
Indications for use:
The i-lipo™ Low Level Laser System is indicated for Non-invasive aesthetic treatment for the temporary reduction in circumference of the waist.
Prescription Use X (21 CFR 801 Subpart D)
AND/OR
Over-The-Counter Use (21 CFR 807 Subpart C)
(PLEASE DO NOT WRITE BELOW THIS LINE - CONTINUE ON ANOTHER PAGE IF NEEDED)
Neil R. Ryden for mxm
(Division Sign-Off)
Division of Surgical, Orthopedic, and Restorative Devices
510(k) Number K111501
F01-1312_1__2